Published on October 22, 2009 at 2:58 AM
Research and Markets (http://www.researchandmarkets.com/research/a51a41/united_arab_emirat) has announced the addition of the "United Arab Emirates Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
The United Arab Emirates Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the United Arab Emirates' pharmaceuticals and healthcare industry.
For the UAE Q409 Pharmaceuticals and Healthcare Report, the author expects the total drug market to increase in value from US$853mn in 2008 to US$1.36bn by 2013, representing a compound annual growth rate (CAGR) of 9.8% in US dollar terms. By 2013, drug spending will account for 0.42% of GDP, only a CAGR of 3.8% since 2008.
In August 2009, UAE-based drugmaker Gulf Pharmaceuticals Industries (Julphar) opened a subsidiary laboratory in Senegal, with a view to manufacturing drugs at affordable prices. The author notes that this expansion will provide a new market for Julphar's products, particularly in Francophone Africa. The decision to locate in West Africa highlights the fact that the drugmaker is targeting emerging markets that have a demand for its core therapeutic areas, including chronic kidney diseases and diabetes. Moreover, the firm is interested in developing business relations within French-speaking Africa. Senegal is highly reliant on imported pharmaceuticals, with most drugs coming from France, India, Morocco and China. A United Arab Emirates firm has invested over US$5.2mn in Indian pharmaceutical manufacturer Anjan Drugs. The funds from Evolvence Capital's Indian investment division, the Evolvence Lifestyle Fund (EILF), are a welcome step toward securing UAE interest in Indian pharmaceuticals.
http://www.researchandmarkets.com